# HERTHENA-Lung01 (NCT04619004)

> HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04619004
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Interventions: Patritumab Deruxtecan (Fixed dose); Patritumab Deruxtecan (Up-Titration)
- Enrollment: 277
- Primary outcome: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)

## Indexed commentary on HERTHENA-Lung01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 27
- YouTube: 22
- Podcasts: 21
- Bluesky threads: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=herthena-lung01-nct04619004

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04619004", "email": "<work email>"}; the inbox owner confirms by the emailed link.